AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02106364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SQ
Study NCT02106364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SQ
Study NCT00949793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscope
Description: Endomicroscopic images are taken at several positions on the tumor.
Study NCT04060771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: prophylaxis of postoperative nausea and vomiting
Study NCT01266018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 (Arginine deiminase pegylated)
Description: ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
Study NCT00656032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: 1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
Study NCT00656032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: 0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
Study NCT02755701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched-chain Amino Acid
Description: BCAA (livact) will be administered 3 times a day during 24 weeks
Study NCT02755701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in the same way
Study NCT00966979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PKR
Description: Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
Study NCT01013688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioblate® Surgical Ablation System
Description: Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
Study NCT05140681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FibReORS with apically positioned flap (apical position)
Description: Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
Study NCT05140681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FibReORS with apically positioned flap (crestal position)
Description: Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
Study NCT03003598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
Study NCT03003598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
Study NCT04415645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-VVZ-149
Description: A single IV infusion of radio-labeled VVZ-149
Study NCT02187367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGF Vaccine
Description: 1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
Study NCT02106195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Study NCT00561717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine and placebo
Description: One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
Study NCT00561717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine and Placebo
Description: One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
Study NCT00561717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine and Placebo
Description: One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
Study NCT00561717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Placebo (spray and Tablet)
Description: One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
Study NCT00944229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOVAZA (Omega-3)
Description: LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
Study NCT00944229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo every 24 hours
Study NCT01854736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax
Description: GRAZAX
Study NCT01854736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02976168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12° head down tilt
Description: supine head down tilt
Study NCT02656550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Transplant of a uterus from either a living donor or a deceased donor.,
Study NCT02341586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lucky Iron Fish - home fortification system
Description: The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
Study NCT02341586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 18 mg elemental iron
Description: This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
Study NCT02341586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Education
Description: This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
Study NCT01458925 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The P1 Check-Cap capsule
Description: The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
Study NCT01347671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRT6005
Description: 25µg/day once daily
Study NCT01347671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRT6005
Description: 75 µg/day once daily
Study NCT01347671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRT6005
Description: 200 µg/day once daily
Study NCT01347671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Once daily
Study NCT01296009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine(Zhuyun Recipe)
Description: The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
Study NCT04060771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: prophylaxis of postoperative nausea and vomiting
Study NCT04124328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALINE + VoM infusion
Description: In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
Study NCT04124328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALINE only
Description: In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
Study NCT00072904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Asparte
Description: Insulin asparte given 0.5 units per carb per meal
Study NCT00072904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repaglinide
Description: 0.5mg tab with meals tid
Study NCT01897792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Study NCT01897792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Study NCT01897792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for Vitamin C)
Description: 0.9% saline administered to mimic Vitamin C
Study NCT01897792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Vitamin E)
Description: Sugar pill administered to mimic Vitamin E
Study NCT01044589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodesign Tissue Repair Graft
Description: Biodesign Tissue Repair Graft reinforcement
Study NCT01044589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overlapping Sphincter Repair
Description: Overlapping Sphincter Repair Alone
Study NCT01044589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overlapping Sphincter Repair
Description: Overlapping Sphincter Repair Alone
Study NCT01234701 — intervention group
Intervention type: OTHER
Intervention: Non-invasive Magnetic Resonance Imaging (MRI)
Description: Conventional pre-operative MRI
Study NCT01234701 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy with an intention to cure
Study NCT01234701 — intervention group
Intervention type: OTHER
Intervention: Histopathology diagnosis of resected liver specimen
Description: Histopathology diagnosis by expert pathologist.
Study NCT02499510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoldenFlow Stent
Description: The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
Study NCT00936676 — intervention group
Intervention type: DRUG
Intervention: rasagiline mesylate
Description: During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
Study NCT04538287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AtaCor StealthTrac Lead
Description: Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
Study NCT03001245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling
Description: Interpersonal Counseling 1+6 sessions
Study NCT03001245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
Study NCT00459914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cpap treatment during sleep
Description: CPAP
Study NCT04019886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological Facilitation of Respiration
Description: Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
Study NCT01741155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 11 μg/m2 administered intravenously over one minute.
Study NCT01741155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 administered as IV infusion.
Study NCT01741155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 administered as IV infusion.
Study NCT03534999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental. This was the group that received TENS
Description: Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
Study NCT03534999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
Study NCT01048099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRO Onc Assay and Treatment
Description: Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
Study NCT01048099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
Study NCT01048099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
Study NCT02882464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC-02 Centrifuge device,2PRF+CAF
Description: In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
Study NCT02882464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PC-02 Centrifuge device,2PRF+CAF
Description: In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
Study NCT02882464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC-02 Centrifuge device, 4 PRF+CAF
Description: Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
Study NCT02882464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PC-02 Centrifuge device, 4 PRF+CAF
Description: Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
Study NCT02882464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG+CAF
Description: The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
Study NCT02882464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG+CAF
Description: The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
Study NCT01056913 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compression Anastomosis Device
Description: Restoring intestinal continuity using the NITI CAR27 device
Study NCT01056913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: follow-up colonoscopy
Description: endoscopic exploration of anastomosis after complete healing
Study NCT02146820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleMax system
Description: Picosecond Laser System for the Treatment of Pigmented Lesions
Study NCT02374437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Study NCT01449786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rMal d 1
Description: 25 µg daily as sublingually administered drops, 16 weeks
Study NCT01449786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rBet v 1
Description: 25 µg daily administered sublingually as drops over 16 weeks
Study NCT01449786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo drops
Description: 25 µg of placebo Drops daily administered sublingually over 16 weeks
Study NCT02922205 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic Linear Cutter Stapler and reloads
Description: Endoscopic Linear Cutter Stapler and reloads
Study NCT02967276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: 500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
Study NCT02967276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
Study NCT01296763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 70 mg/m2 IV, Days 1 and 8
Study NCT01296763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV, Days 1 and 8
Study NCT01296763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (for levels 1 and 5)
Description: Olaparib 100 mg bid oral, Days 1 and 8
Study NCT01296763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (for dose level 2)
Description: Olaparib 100mg bid oral, Day 1-3, Day 8-10
Study NCT01296763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: Mitomycin 5 mg/m2 IV, Day 1
Study NCT03964051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: Omalizumab 300 mg for subcutaneous injection
Study NCT02036437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misotac® Sigma Pharmaceutical Industries
Description: The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
Study NCT02036437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 3 mg
Description: Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
Study NCT04461769 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Electrical Stimulation
Description: Oscillating electrical current
Study NCT04461769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Stimulation
Description: Oscillating electrical current